Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug binding...
Renal Failure: Dose Adjustments01:11

Renal Failure: Dose Adjustments

In patients with renal impairment, drugs undergo significant changes in their pharmacokinetics, which require dosage adjustments to ensure safe and effective therapy.
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess the...
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment01:08

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug01:14

Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug

In pharmacotherapy, monitoring drug concentrations is paramount, especially for drugs whose therapeutic effects hinge on both the active compound and its metabolite. Hepatic impairment profoundly influences drug potency by altering liver function. If the drug is more potent than its metabolite, impaired liver function amplifies drug activity due to elevated drug concentration levels. Conversely, if the metabolite holds greater potency, diminished liver function diminishes drug activity by...
Factors Affecting Renal Clearance: Renal Impairment01:17

Factors Affecting Renal Clearance: Renal Impairment

Renal dysfunction significantly impairs the renal clearance of drugs, leading to potential complications in drug therapy. Renal failure, which can be caused by various factors, poses a significant challenge in the elimination of drugs from the body.
One condition associated with renal failure is uremia. Uremia is characterized by impaired glomerular filtration and fluid accumulation in the body. This condition hinders the renal clearance of drugs, resulting in drug accumulation and potential...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Cardiopulmonary Baroreflex Control of Renal Sympathetic Nerve Activity Is Impaired in Dogs With Left Ventricular Dysfunction.

Journal of cardiac failure·2019
Same author

Does the benefit from treating to lower blood pressure targets vary with age? A systematic review and meta-analysis.

Journal of hypertension·2019
Same author

History and Justification of a National Blood Pressure Measurement Validated Device Listing.

Hypertension (Dallas, Tex. : 1979)·2018
Same author

Hydrochlorothiazide vs chlorthalidone, indapamide, and potassium-sparing/hydrochlorothiazide diuretics for reducing left ventricular hypertrophy: A systematic review and meta-analysis.

Journal of clinical hypertension (Greenwich, Conn.)·2018
Same author

Subcutaneous Furosemide in Heart Failure: Pharmacokinetic Characteristics of a Newly Buffered Solution.

JACC. Basic to translational science·2018
Same author

Hydrochlorothiazide and alternative diuretics versus renin-angiotensin system inhibitors for the regression of left ventricular hypertrophy: a head-to-head meta-analysis.

Journal of hypertension·2018
Same journal

The Spectrum of Genetic Causes of Familial Hypercholesterolemia Phenotype.

Current atherosclerosis reports·2026
Same journal

Targeting LDL Across the Whole Spectrum of Chronic Kidney Disease: From Pathophysiology to Novel Treatments.

Current atherosclerosis reports·2026
Same journal

Overview of Novel Mechanisms in Obesity Pharmacotherapy and Implications for Cardiovascular Disease: A Narrative Review.

Current atherosclerosis reports·2026
Same journal

Artificial and Other Non-Nutritive Sweeteners, the Microbiome, and Cardiometabolic Health.

Current atherosclerosis reports·2026
Same journal

Single-cell Technologies in Atherosclerosis: Uncovering Cellular Heterogeneity, Mechanisms, and Therapeutic Opportunities.

Current atherosclerosis reports·2026
Same journal

Primary Prevention of Dyslipidemia: 10 Practice-Changing Takeaways from the 2026 ACC/AHA Multisociety Guideline.

Current atherosclerosis reports·2026
See all related articles

Related Experiment Videos

Fibrate therapy and renal function.

Domenic A Sica1

  • 1Clinical Pharmacology and Hypertension, Virginia Commonwealth University Health System, Sanger Hall, Room 8-062, Richmond, VA 23298-0160, USA. dsica@mcvh-vcu.edu

Current Atherosclerosis Reports
|August 12, 2009
PubMed
Summary
This summary is machine-generated.

Fibrates, used to lower lipids, can cause a reversible increase in serum creatinine. This rise may not indicate true kidney damage, but monitoring is advised, especially for those with existing kidney issues.

Related Experiment Videos

Area of Science:

  • Pharmacology
  • Nephrology
  • Biochemistry

Background:

  • Fibrates are lipid-lowering drugs often used after statins.
  • A common side effect is a reversible increase in serum creatinine.
  • The clinical significance of this rise in serum creatinine is not fully understood.

Purpose of the Study:

  • To investigate the cause of elevated serum creatinine in patients taking fibrates.
  • To determine if fibrate-induced serum creatinine increases reflect true renal dysfunction.
  • To provide guidance on monitoring and managing this adverse effect.

Main Methods:

  • Review of existing literature on fibrate pharmacology and renal effects.
  • Analysis of proposed mechanisms for serum creatinine elevation.
  • Clinical recommendations based on observed patient data.

Main Results:

  • Fibrates may increase creatinine production, falsely elevating serum levels.
  • Alternatively, reduced prostaglandin production could impact true renal function.
  • A 30% increase in serum creatinine warrants consideration of fibrate discontinuation.

Conclusions:

  • The rise in serum creatinine with fibrate use requires careful evaluation.
  • Routine monitoring of serum creatinine is recommended for patients on fibrates.
  • Discontinuation of fibrates may be necessary if a significant, unexplained increase in serum creatinine occurs.